Literature DB >> 7527648

G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft.

P Dreger1, T Haferlach, V Eckstein, S Jacobs, M Suttorp, H Löffler, W Müller-Ruchholtz, N Schmitz.   

Abstract

Allogeneic transplantation of peripheral blood progenitor cells (PBPC) makes the general anaesthesia of the donor unnecessary and may result in more rapid engraftment and faster recovery of the immune system. We have studied G-CSF-mediated PBPC mobilization in healthy donors and analysed the cellular composition of the resulting PBPC grafts. PBPC grafts were obtained from nine healthy donors (18-67 years old) for allogeneic or syngeneic transplantation. Six donors received 10 micrograms/kg G-CSF per day, the others 5-6 micrograms/kg. Mobilization and harvesting were well tolerated except for moderate bone pain which occurred in all donors primed with 10 micrograms/kg. With 10 micrograms/kg, a 31-fold (9-62) enrichment of circulating CD34+ cells was observed with peak values constantly occurring on day 5 after the start of G-CSF administration. Starting harvest on day 5, one to three collections on consecutive days yielded 5.5 x 10(6)/kg (0.9-10.7) CD34+ cells, 219 x 10(6)/kg (106-314) T cells, and 34 x 10(6)/kg (23-67) NK cells per 10 litres leukapheresis volume. Altogether, PBPC grafts contained 3 times more CD34+ cells, 7 times more T cells, and 20 times more NK cells than five allogeneic marrow grafts that were analysed for comparison. The yield of CD34+ cells per 10 litres apheresis volume as well as the height of the CD34+ peak in peripheral blood were inversely correlated to the age of the donor. In the donors primed with 5-6 micrograms/kg G-CSF the increase of circulating CD34+ cells (4-7-fold enrichment) and the CD34+ cell yield per 10 litres leukapheresis volume (1 x 10(6)/kg [0.8-2.2]) was much smaller compared with the 10 micrograms/kg group. In conclusion, sufficient amounts of PBPC capable of restoring haemopoiesis in allogeneic recipients can be mobilized safely by administration of G-CSF (10 micrograms/kg s.c. for 5 d) in healthy donors, and harvested with one or two leukapheresis procedures. Whether the large numbers of T-cells and NK cells that are contained in the collection products may influence graft-versus-host and graft-versus-leukaemia reactivities of PBPC grafts remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527648     DOI: 10.1111/j.1365-2141.1994.tb08321.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  26 in total

Review 1.  Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4.

Authors:  M P Rettig; G Ansstas; J F DiPersio
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

Review 2.  G-CSF in Healthy Allogeneic Stem Cell Donors.

Authors:  Kristina Hölig
Journal:  Transfus Med Hemother       Date:  2013-07-22       Impact factor: 3.747

Review 3.  Molecular characterization of CD34+ human hematopoietic progenitor cells.

Authors:  W Knapp; H Strobl; C Scheinecker; C Bello-Fernandez; O Majdic
Journal:  Ann Hematol       Date:  1995-06       Impact factor: 3.673

Review 4.  Cell therapy of peripheral arterial disease: from experimental findings to clinical trials.

Authors:  Zankhana Raval; Douglas W Losordo
Journal:  Circ Res       Date:  2013-04-26       Impact factor: 17.367

5.  Flashback 1997: collection of hematopoietic progenitor cells by peripheral blood apheresis after stimulation with granulocyte-colony-stimulating factor.

Authors:  Willy A Flegel; Karen M Byrne; Harvey G Klein
Journal:  Transfusion       Date:  2017-09-18       Impact factor: 3.157

Review 6.  Potential benefits of allogeneic bone marrow mesenchymal stem cells for wound healing.

Authors:  Alexander R Badiavas; Evangelos V Badiavas
Journal:  Expert Opin Biol Ther       Date:  2011-08-20       Impact factor: 4.388

7.  Long-term Tolerance Toward Haploidentical Vascularized Composite Allograft Transplantation in a Canine Model Using Bone Marrow or Mobilized Stem Cells.

Authors:  Jeff Chang; Scott S Graves; Tiffany Butts-Miwongtum; George E Sale; Rainer Storb; David Woodbridge Mathes
Journal:  Transplantation       Date:  2016-12       Impact factor: 4.939

Review 8.  Graft failure after allogeneic hematopoietic cell transplantation.

Authors:  Jonas Mattsson; Olle Ringdén; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2008-01       Impact factor: 5.742

9.  Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow.

Authors:  Gabriel J Tsao; Jessica A Allen; Kathryn A Logronio; Laura C Lazzeroni; Judith A Shizuru
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-17       Impact factor: 11.205

Review 10.  Clinical application of allogeneic peripheral blood stem cells transplantation.

Authors:  J Tanaka; M Kasai; M Imamura; M Asaka
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.